Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System (TriStar)
Primary Purpose
Tricuspid Regurgitation
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Transcatheter Annuloplasty
Sponsored by
About this trial
This is an interventional treatment trial for Tricuspid Regurgitation
Eligibility Criteria
Inclusion Criteria:
- Age ≥60, male or female;
- patients with severe or above secondary tricuspid regurgitation (TR≥4+) (secondary tricuspid regurgitation: tricuspid regurgitation caused by right atrial lesions, right ventricular cardiomyopathy, right ventricular myocardial infarction, left ventricular valvular disease, congenital heart disease and other diseases);
- A multidisciplinary cardiac team (at least 2 doctors) consisting of cardiovascular physicians, cardiovascular surgeons, radiologists, anesthesiologists, etc., considered the subject to be at high risk for surgery and expected to benefit from tricuspid valve repair;
- Left ventricular ejection fraction LVEF≥40%;
- The subject voluntarily participates in the clinical trial and agrees or his/her guardian agrees to sign the informed consent.
- Tricuspid regurgitation symptoms, such as chest tightness, asthma, shortness of breath, lower limb edema, ascites;
- NYHA grade 2 to 4;
- Patients who received tricuspid valve optimal drug therapy for ≥ 30 days were in stable condition;
- In the case of the following diseases: mitral regurgitation, atrial fibrillation, coronary disease and heart failure, drug treatment should be ≥ 30 days or ≥ 30 days after instrumental treatment and the patient's condition is stable.
Exclusion Criteria:
- patients with primary tricuspid regurgitation;
- Patients with systolic pulmonary artery pressure ≥55 mmHg;
- Patients with tricuspid valve or annuloplasty or tricuspid related procedure;
- Patients with posterior tricuspid annulus calcification;
- Evidence of mass, thrombosis or vegetations in the heart, jugular vein and superior vena cava;
- patients with moderate or higher aortic stenosis, mitral stenosis, aortic regurgitation or mitral regurgitation;
- patients with severely uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg);
- Percutaneous coronary intervention within 1 month;
- myocardial infarction or known unstable angina within 1 month;
- Cerebrovascular accident within the past 3 months;
- patients with active endocarditis or active rheumatic heart disease;
- Patients with coagulation dysfunction, hypercoagulability or anemia (hemoglobin < 90 g/L);
- patients with acute infection or other severe infection;
- Patients with active peptic ulcer or active gastrointestinal bleeding;
- severe end-stage diseases (such as malignant tumor, severe lung disease, liver disease, renal failure) with a life expectancy of less than one year;
- Patients with known allergies or contraindications to the raw materials or drugs (such as antiplatelet drugs and anticoagulants) of the test products;
- Persons addicted to alcohol, drugs or drugs;
- Patients with cognitive impairment;
- patients with histories of epilepsy or mental illness;
- Participate in any other clinical trial (other than a registry study) within 30 days prior to signing the informed consent;
- have a previous implantation of a pacemaker or defibrillator, or plan to implant a pacemaker or defibrillator;
- Tricuspid stenosis;
- Ebstain syndrome;
- The anatomy of tricuspid annulus could not be assessed by TEE and TTE;
- Hemodynamic instability;
- chronic dialysis patients;
- women who are pregnant during pregnancy, breast-feeding or during the clinical study;
- Other conditions that the investigator considers inappropriate for participation in the clinical trial.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
K-clipTM transcatheter annuloplasty system
Arm Description
Outcomes
Primary Outcome Measures
All-cause mortality
Change of Tricuspid Regurgitation Grade
Change of Tricuspid Regurgitation Grade assessed by corelab than baseline
Secondary Outcome Measures
The success rate of post operation 12 months
Success rate of device implantation
Change in echocardiographic parameters
Change in echocardiographic parameters:Tricuspid annulus A-P diameter(mm)、 Tricuspid annulus perimeter(mm)、Tricuspid annulus area(cm2)、Vena contracta width(mm)、EROA(cm2)、Regurgitation volume(ml)、IVC(mm)。
Change of Tricuspid Regurgitation Grade
NYHA
6 minutes walk distance
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Full Information
NCT ID
NCT05173233
First Posted
December 27, 2021
Last Updated
April 20, 2022
Sponsor
Shanghai Huihe Medical Technology Co., Ltd
1. Study Identification
Unique Protocol Identification Number
NCT05173233
Brief Title
Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System
Acronym
TriStar
Official Title
Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
May 15, 2022 (Anticipated)
Primary Completion Date
May 15, 2023 (Anticipated)
Study Completion Date
May 15, 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shanghai Huihe Medical Technology Co., Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The present clinical trial is performed to evaluate the effectiveness and safety of transcatheter tricuspid annuloplasty system manufactured by Shanghai Huihe Healthcare technology Co.,Ltd. for the treatment of subjects with severe or worse tricuspid regurgitation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tricuspid Regurgitation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
67 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
K-clipTM transcatheter annuloplasty system
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Transcatheter Annuloplasty
Intervention Description
Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
Primary Outcome Measure Information:
Title
All-cause mortality
Time Frame
1-year after operation
Title
Change of Tricuspid Regurgitation Grade
Description
Change of Tricuspid Regurgitation Grade assessed by corelab than baseline
Time Frame
1-year after operation
Secondary Outcome Measure Information:
Title
The success rate of post operation 12 months
Time Frame
2 years, 3years, 4 years, 5 years
Title
Success rate of device implantation
Time Frame
intra-procedure
Title
Change in echocardiographic parameters
Description
Change in echocardiographic parameters:Tricuspid annulus A-P diameter(mm)、 Tricuspid annulus perimeter(mm)、Tricuspid annulus area(cm2)、Vena contracta width(mm)、EROA(cm2)、Regurgitation volume(ml)、IVC(mm)。
Time Frame
1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years
Title
Change of Tricuspid Regurgitation Grade
Time Frame
1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years
Title
NYHA
Time Frame
1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years
Title
6 minutes walk distance
Time Frame
1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years
Title
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time Frame
1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥60, male or female;
patients with severe or above secondary tricuspid regurgitation (TR≥4+) (secondary tricuspid regurgitation: tricuspid regurgitation caused by right atrial lesions, right ventricular cardiomyopathy, right ventricular myocardial infarction, left ventricular valvular disease, congenital heart disease and other diseases);
A multidisciplinary cardiac team (at least 2 doctors) consisting of cardiovascular physicians, cardiovascular surgeons, radiologists, anesthesiologists, etc., considered the subject to be at high risk for surgery and expected to benefit from tricuspid valve repair;
Left ventricular ejection fraction LVEF≥40%;
The subject voluntarily participates in the clinical trial and agrees or his/her guardian agrees to sign the informed consent.
Tricuspid regurgitation symptoms, such as chest tightness, asthma, shortness of breath, lower limb edema, ascites;
NYHA grade 2 to 4;
Patients who received tricuspid valve optimal drug therapy for ≥ 30 days were in stable condition;
In the case of the following diseases: mitral regurgitation, atrial fibrillation, coronary disease and heart failure, drug treatment should be ≥ 30 days or ≥ 30 days after instrumental treatment and the patient's condition is stable.
Exclusion Criteria:
patients with primary tricuspid regurgitation;
Patients with systolic pulmonary artery pressure ≥55 mmHg;
Patients with tricuspid valve or annuloplasty or tricuspid related procedure;
Patients with posterior tricuspid annulus calcification;
Evidence of mass, thrombosis or vegetations in the heart, jugular vein and superior vena cava;
patients with moderate or higher aortic stenosis, mitral stenosis, aortic regurgitation or mitral regurgitation;
patients with severely uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg);
Percutaneous coronary intervention within 1 month;
myocardial infarction or known unstable angina within 1 month;
Cerebrovascular accident within the past 3 months;
patients with active endocarditis or active rheumatic heart disease;
Patients with coagulation dysfunction, hypercoagulability or anemia (hemoglobin < 90 g/L);
patients with acute infection or other severe infection;
Patients with active peptic ulcer or active gastrointestinal bleeding;
severe end-stage diseases (such as malignant tumor, severe lung disease, liver disease, renal failure) with a life expectancy of less than one year;
Patients with known allergies or contraindications to the raw materials or drugs (such as antiplatelet drugs and anticoagulants) of the test products;
Persons addicted to alcohol, drugs or drugs;
Patients with cognitive impairment;
patients with histories of epilepsy or mental illness;
Participate in any other clinical trial (other than a registry study) within 30 days prior to signing the informed consent;
have a previous implantation of a pacemaker or defibrillator, or plan to implant a pacemaker or defibrillator;
Tricuspid stenosis;
Ebstain syndrome;
The anatomy of tricuspid annulus could not be assessed by TEE and TTE;
Hemodynamic instability;
chronic dialysis patients;
women who are pregnant during pregnancy, breast-feeding or during the clinical study;
Other conditions that the investigator considers inappropriate for participation in the clinical trial.
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System
We'll reach out to this number within 24 hrs